Smart dosing of antibiotics may cut infection risk after colon surgery
NCT ID NCT05253339
First seen Oct 01, 2025 · Last updated Jun 19, 2026 · Updated 28 times
Summary
This study tested whether giving the antibiotic cefoxitin using a target-controlled infusion pump works better than the standard method to prevent surgical site infections in patients having colon or rectal surgery. About 2,500 adults took part. The goal was to see if the new method lowers infection rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTI-BACTERIAL AGENTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Asan Medical Center
Seoul, Songpa-Gu,, 05505, South Korea
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cefoxitin
What this could lead to
If successful, this could show that target-controlled infusion reduces surgical site infections better than the standard method.
What could go wrong
This is a completed single-center trial; results may not apply to other hospitals or surgeries. The benefit over standard dosing may be small or absent.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.